Pancrelipase

Creon, Zenpep, Pancreaze and Pertzye indicate adult/pediatric exocrine pancreatic insufficiency. Labels include birth-to-12-month dosing despite different supporting trial ages. They are porcine lipase/protease/amylase preparations; no nonporcine or OTC digestive-supplement equivalence is inferred.

Viokace with a proton pump inhibitor treats EPI due to chronic pancreatitis or pancreatectomy in adults. It is not enteric coated, and pediatric safety/effectiveness are unestablished. Do not transfer broad capsule indications or infant dosing to Viokace.

Selected delayed-release capsules: at age ≥ 4 start 500 lipase units/kg/meal; age > 12 months to < 4 start 1,000 units/kg/meal. Creon additionally gives adult chronic-pancreatitis/pancreatectomy start 500–1,000 units/kg/meal. Viokace adult start is 500 units/kg/meal with a PPI. Titrate to malabsorption response and nutritional status; with snacks use about half the prescribed meal dose and count the entire daily total.

At age > 12 months for capsules, and adult Viokace: do not exceed 2,500 lipase units/kg/meal, 10,000 units/kg/day or 4,000 units/g dietary fat/day without further investigation. Zenpep/Pancreaze dose-titration text uses “less than 4,000” for its fat-based target; preserve the prescriber’s exact plan. Higher doses need documented efficacy through fecal-fat or malabsorption/nutrition measures. Monitor symptoms and retitrate after a supervised product switch; do not assume the same capsule count or protease/amylase ratio.

Give immediately before each breastfeeding session or each 120 mL formula feed, followed by breast milk/formula. The product-specific lipase units below differ; do not interchange the infant dose. Open the correct capsule, give entire contents directly into the mouth or approved acidic soft food, never crush and inspect the mouth for retained beads. Do not mix directly into a milk/formula bottle.

Take with meals/snacks; swallow whole with adequate liquid. Delayed-release capsules can be opened onto a small amount of label-approved acidic soft food at pH ≤ 4.5 and swallowed immediately without chewing; do not save the mixture. Creon names applesauce, bananas/plain Greek yogurt; Zenpep applesauce, bananas/pears; Pancreaze/Pertzye applesauce. Viokace tablets must be swallowed whole with water and the prescribed PPI. If missed, take the next prescribed dose with the next meal/snack or infant feed; never double.

Only Pertzye 4,000-unit capsule contents through a gastrostomy tube ≥ 14 French; no more than two capsules at a time. Mix one/two capsules with at least 10 mL applesauce without crushing; prepare immediately in a 35 mL slip-tip syringe, remove residual air and connect directly to the feeding port. Give with steady pressure (IFU about 10–12 seconds), then flush about 10 mL water; repeat for larger prescribed doses. Discard unused mixture. Other strengths, narrower tubes and other brands do not acquire this method by analogy.

The five selected U.S. labels list no formal contraindications. This does not remove severe hypersensitivity precautions, fibrosing-colonopathy monitoring or product/age/administration limits. Viokace’s PPI must be assessed separately for its own suitability.

The selected current labels have no boxed warning. Fibrosing colonopathy, hyperuricemia, mucosal injury and severe allergy remain prominent labeled risks.

Clinical experiences differ: Creon vomiting/dizziness/cough and GI/glucose events in selected trials; Zenpep headache, bruising, cough/early satiety and pediatric GI symptoms; Pancreaze diarrhea/vomiting; Pertzye diarrhea/dyspepsia/cough; Viokace anal itching and biliary stones in a small adult trial. Do not compare rates across studies as product rankings. Postmarketing class reports include GI obstruction/colonopathy, allergy and skin/liver/muscle symptoms. High-dose overdose exposure may cause uric-acid and bowel complications; obtain medical/Poison Help review rather than self-treat or exceed the plan.

These enzymes are not CYP/transport substrates; such mediated interactions are not expected. Viokace requires a prescribed PPI to protect gastric enzyme activity, with that drug’s own interactions/risks reviewed. Delayed-release capsule labels do not automatically require a PPI for every patient. Food pH, crushing and unverified tube preparation can disrupt delivery; follow the exact product method.

The four delayed-release products establish pediatric EPI use with different supporting studies and birth-to-12-month directions. Viokace pediatric effectiveness/safety are unestablished and gastric degradation may yield inadequate nutrition. Children below 12 are particularly relevant to high-dose colonopathy reports. Geriatric trials were limited; no universal age-only adjustment is supplied, but disease, nutrition and tolerance need assessment.

Published pancrelipase case reports have not identified a drug-associated major-birth-defect/miscarriage signal. Minimal systemic absorption makes fetal or clinically relevant milk exposure unlikely; milk/infant-effect data and reproductive studies are limited or absent. Balance breastfeeding benefits, maternal nutritional need and potential infant risks; do not claim absolute safety.

Selected labels provide no numeric renal/hepatic dose-adjustment algorithm; local digestion and nutritional response drive titration. Renal disease/gout/hyperuricemia increase concern about purine-related urate effects and justify consideration of monitoring. Do not infer that negligible systemic enzyme absorption removes all product risks.

Lipases, proteases and amylases hydrolyze fats, proteins and starch in the duodenum/proximal small intestine, improving nutrient absorption. Enzymes are not absorbed from the GI tract in appreciable amounts; no clinically useful serum peak/protein-binding/half-life dose model is established in these labels. Enteric-coated beads delay release, whereas Viokace needs acid suppression. Lipase activity units and the product-specific enzyme ratios govern prescribing, not milligram interchangeability.

Follow stool quality/steatorrhea, pain/bloating, weight/growth and nutritional status with the clinical team. Review actual meal/snack doses, dietary fat, adherence, pH/whole-bead technique and changes after switching. Higher doses need efficacy documentation and colonopathy assessment. Consider blood uric acid in gout/renal impairment/hyperuricemia; inspect infant mouths for retained beads and assess severe-allergy symptoms. No routine serum enzyme-drug concentration is specified.

Use the prescribed product and lipase-unit dose with food; do not independently switch, crush, chew or double. Follow the exact infant capsule and feeding method; Viokace requires its PPI, and only the restricted Pertzye method is described for tubes. Report persistent malabsorption, unusual/severe pain, distention, constipation, vomiting or joint inflammation. Breathing trouble/swelling/rash suggest severe allergy and need urgent assessment. Keep desiccant and moisture-protective packaging as instructed.

Creon 12,000 lipase / 38,000 protease / 60,000 amylase USP units: brown opaque cap marked CREON 1212, transparent body; selected 100-capsule package NDC 0032-1212-01. Verify actual package and shell variant; strength is enzyme activity, not 12,000 mg.

Lipase USP-unit strengths: Creon 3,000, 6,000, 12,000, 24,000 and 36,000; Zenpep 3,000, 5,000, 10,000, 15,000, 20,000, 25,000, 40,000 and 60,000; Pancreaze 2,600, 4,200, 10,500, 16,800, 21,000 and 37,000; Pertzye 4,000, 8,000, 16,000 and 24,000, all delayed-release capsules. Viokace non-enteric tablets: 10,440 or 20,880 lipase units. Verify each product’s protease/amylase ratio from its label rather than substitute by lipase or capsule count alone. Current FDA application records list these selected strengths Prescription, not pharmacy stock.

Keep moisture-protective packaging tightly closed and retain the desiccant; do not eat it. Creon: 15–25°C; 25–40°C excursions up to 30 days, discard for higher temperature or moisture > 70%, original container. Zenpep original: 20–25°C; brief 15–40°C excursions for 24 hours; approved repackaged HDPE: up to 30°C for 6 months, 15–40°C excursions up to 30 days. Pancreaze: 15–25°C, up to 40°C for 24 hours, original bottle. Pertzye: 20–25°C, 15–40°C excursions up to 30 days, original/equivalent airtight container. Viokace: 20–25°C, up to 40°C for 24 hours, original bottle. Follow package expiry and do not store food mixtures.